MLYS vs MRNA: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MLYS and MRNA share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MLYS and MRNA exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Mineralys Therapeutics (Nasdaq: MLYS), headquartered in Radnor, Pennsylvania, is a clinical-stage biopharmaceutical company focused on hypertension and related conditions driven by dysregulated aldosterone. Its lead and essentially only asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor being developed for uncontrolled and resistant hypertension, with additional programs exploring chronic kidney disease (CKD) and obstructive sleep apnea (OSA). The company completed its Phase 3 program (including the Launch-HTN and Advance-HTN trials) and submitted a New Drug Application that the FDA accepted, with a PDUFA target action date of December 22, 2026, positioning Mineralys as it transitions toward a potential pre-commercial stage.

Full MLYS guide

Moderna is a Cambridge, Massachusetts biotechnology company built entirely around messenger RNA (mRNA) technology, the platform behind its Spikevax COVID-19 vaccine. After generating enormous pandemic-era revenue, demand has fallen sharply, and the company is trying to broaden beyond COVID into a wider vaccine and therapeutics franchise. Its approved and near-market products include Spikevax, the mRESVIA RSV vaccine for older adults, and newer respiratory approvals in Europe (mNEXSPIKE and the mCOMBRIAX combination shot), while its most watched late-stage assets are the mRNA-1010 seasonal flu vaccine and intismeran autogene (mRNA-4157), a personalized cancer vaccine developed with Merck.

Full MRNA guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MLYS drivers: Lorundrostat FDA decision; Large uncontrolled-hypertension market.
• MRNA drivers: Respiratory franchise beyond COVID; Oncology optionality via Merck partnership.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is single-asset concentration: essentially the entire thesis depends on lorundrostat, so an FDA complete response letter, label restrictions, or safety concerns would be severe. For MRNA, revenue has fallen dramatically from pandemic highs and COVID demand remains uncertain, so the current business does not cover operating costs.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MLYS if you believe its drivers more; MRNA if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MLYS and MRNA guides.

MLYS. Standard valuation multiples do not apply to Mineralys because it has no product revenue and posts ongoing losses funded by its cash balance. The roughly $2.3 billion market value reflects the market's probability-weighted view of lorundrostat's approval and future sales, not trailing fundamentals. Cash of about $646 million as of March 2026, with runway guided into 2028, is the key financial cushion ahead of the December 2026 FDA decision.

MRNA. MRNA trades on pipeline potential rather than current earnings, since it is loss-making with revenue far below its pandemic peak. Traditional multiples like P/E are not meaningful while the company is unprofitable, so the market is effectively pricing the odds of flu, combination, and cancer-vaccine programs succeeding. The multibillion-dollar cash balance is a key reason the company can fund that pipeline toward its 2028 break-even goal.

Headline figures (approximate, JUNE 2026): MLYS shows product revenue (ttm) ~$0 (pre-commercial), cash & investments ~$646M (Mar 2026), q1 2026 net loss ~$39M, q1 2026 r&d expense ~$24M; MRNA shows market cap ~$20 billion, q1 2026 revenue ~$400 million, q1 2026 net loss ~$1.3 billion (incl. ~$878M legal charge), 2026 revenue growth guidance up to ~10%.

MLYS and MRNA are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MLYS and MRNA exposure against your real portfolio. It is not an investment adviser.